title: Live attenuated vaccines against pertussis.
abstract: The intensive use of pertussis vaccines has dramatically reduced the incidence of whooping cough during the 20th century. However, recent outbreaks in countries with high vaccination coverage illustrate the shortcomings of current vaccination regimens, and immunity induced by the most recent, acellular vaccines wanes much faster than anticipated. As an alternative, live attenuated vaccine candidates have recently been developed in order to mimic natural infection, which induces long-lasting immunity. One of them has successfully completed a Phase I trial in humans and is now undergoing further product and clinical developments. This article describes the development of such vaccines, discusses their advantages over existing vaccines and their interesting bystander properties as powerful anti-inflammatory agents, which widens their potential use far beyond that for protection against whooping cough.
authors.affiliation: Institut Pasteur de Lille, Center for Infection and Immunity of Lille, 1, rue du Prof. Calmette, F-59019 Lille, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Locht
authors.forename: Nathalie
authors.initials: N
authors.lastname: Mielcarek
mesh_terms: D017321:Clinical Trials, Phase I as Topic; D004196:Disease Outbreaks; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D010567:Pertussis Vaccine / Q000276:immunology* / Q000302:isolation & purification*; D014613:Vaccines, Attenuated / Q000276:immunology / Q000302:isolation & purification; D014917:Whooping Cough / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*
chemical_list: D010567:Pertussis Vaccine; D014613:Vaccines, Attenuated
keywords: Pertussis; inflammation; live attenuated; multivalent vaccine; nasal vaccine